#Canada #Toronto #Perimeter Medical Imaging #Claire OCT #AI-enabled imaging

Perimeter's Financial Triumph in 2025

Perimeter Medical Imaging AI, Inc., a leader in medical technology, has released its preliminary unaudited fourth quarter and full year financial results for 2025, showcasing unprecedented growth and the successful launch of innovative medical devices. Reporting significant revenue increases and improved operational performance, the company is positioning itself as a frontrunner in the fight against breast cancer through advanced imaging technology.

In March 2026, Perimeter's CEO, Adrian Mendes, expressed optimism about the company’s trajectory, emphasizing 2025 as a pivotal year that would shape the future of their operations and growth in the medical imaging sector. The revenue for the fourth quarter of 2025 reached $711,000, marking a remarkable 143% increase compared to the same period last year, while the full year revenue stood at approximately $2.3 million—an impressive rise of 172% year-over-year. Not only did this financial surge reflect the strong market adoption of Perimeter’s products, but it also underscored the successful implementation of their strategic roadmap aimed at expanding the availability of their groundbreaking imaging solutions.

Advancements in Breast Cancer Surgery Technology

A cornerstone of Perimeter's success in 2025 was the advancement of their S-Series OCT platform and the development of the Claire™ device, the first AI-enabled imaging technology to gain FDA PMA approval specifically for intraoperative breast cancer margin assessment. The Claire device delivers high-resolution images at unprecedented depths, significantly enhancing the capacity for surgeons to evaluate tumor margins during breast-conserving surgeries effectively. With an ability to detect previously unidentifiable areas of cancer, Claire holds the potential to greatly reduce the necessity for subsequent surgical procedures, thereby improving patient outcomes.

Mendes highlighted the significance of FDA’s approval, stating it validates Perimeter's approach and its commitment to innovation in breast cancer surgeries. The company is prepared to launch Claire commercially in the second quarter of 2026, which is expected to drive further revenues and establish Perimeter's technology as a standard in clinical practice.

Expanding Market Presence

In 2025, Perimeter not only focused on innovation but also made strategic partnerships to broaden its market reach. The company's collaboration with leading healthcare institutions across the United States has led to significant adoption rates for their S-Series OCT product. The deployment of these systems in hospitals like HCA HealthONE in Colorado and the Intermountain Healthcare system in Utah represents a testament to the trust and interest in Perimeter's technology among healthcare professionals.

Financial Overview and Future Prospects

Despite operating expenses amounting to $14.4 million for the year, down from $19.4 million in 2024, Perimeter noted an improvement in its net loss, which narrowed to $12.9 million, or $0.16 per share. This reduction highlights the company's strengthened operational efficiency amid ongoing development and market expansion. Perimeter's cash position as of year-end 2025 stood at approximately $2.5 million, reflecting a 36% decrease in cash used in operating activities compared to the previous year.

Looking ahead, Perimeter anticipates filing its annual audited financial statements by early April 2026, which will provide further insights into their financial health and operational strategies. As the company readies itself for the commercial launch of Claire and continues to enhance its portfolio, it remains focused on creating sustained revenue growth and delivering value to stakeholders in the healthcare sector.

Conclusion

With its innovative AI technologies and the successful commercial launch of groundbreaking devices, Perimeter Medical Imaging is not only transforming breast cancer surgery but is also solidifying its place as a leader in the medical technology industry. The results from 2025 portray a company with a clear vision, robust execution, and the commitment necessary to improve patient outcomes significantly as it moves forward into the future.